- Home
- SAFT vs NRIX Comparison
SAFT vs NRIX Comparison
Compare SAFT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFT
- NRIX
- Stock Information
- Founded
- SAFT 1979
- NRIX 2009
- Country
- SAFT United States
- NRIX United States
- Employees
- SAFT N/A
- NRIX N/A
- Industry
- SAFT Property-Casualty Insurers
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- SAFT Finance
- NRIX Health Care
- Exchange
- SAFT Nasdaq
- NRIX Nasdaq
- Market Cap
- SAFT 1.3B
- NRIX 1.3B
- IPO Year
- SAFT N/A
- NRIX 2020
- Fundamental
- Price
- SAFT $84.86
- NRIX $22.92
- Analyst Decision
- SAFT
- NRIX Strong Buy
- Analyst Count
- SAFT 0
- NRIX 15
- Target Price
- SAFT N/A
- NRIX $29.33
- AVG Volume (30 Days)
- SAFT 49.7K
- NRIX 953.2K
- Earning Date
- SAFT 11-05-2024
- NRIX 10-11-2024
- Dividend Yield
- SAFT 4.24%
- NRIX N/A
- EPS Growth
- SAFT 139.36
- NRIX N/A
- EPS
- SAFT 5.07
- NRIX N/A
- Revenue
- SAFT $1,091,694,000.00
- NRIX $56,424,000.00
- Revenue This Year
- SAFT N/A
- NRIX N/A
- Revenue Next Year
- SAFT N/A
- NRIX $7.17
- P/E Ratio
- SAFT $16.73
- NRIX N/A
- Revenue Growth
- SAFT 21.41
- NRIX N/A
- 52 Week Low
- SAFT $71.99
- NRIX $5.65
- 52 Week High
- SAFT $90.00
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- SAFT 56.63
- NRIX 38.26
- Support Level
- SAFT $85.01
- NRIX $26.48
- Resistance Level
- SAFT $88.39
- NRIX $29.56
- Average True Range (ATR)
- SAFT 1.69
- NRIX 1.56
- MACD
- SAFT 0.49
- NRIX -0.19
- Stochastic Oscillator
- SAFT 60.12
- NRIX 0.52
About SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.